Clinical trials: Anlotinib
Small Cell Lung Cancer Limited Stage
Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
The purpose of this study is to evaluate the tolerability and toxicity of different dose of anlotinib combination with concurrent chemoradiotherapy in the treatment of limited-stage SCLC patients.
- Trial name
- NCT04882033
- Testing
- Concurrent chemoradiotherapy plus anlotinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Resectable Locally Advanced Non-small Cell Lung Cancer
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
This is a multicenter, randomized, open label, phase II study.
- Trial name
- ALTER-L043 (NCT04846634)
- Testing
- Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Refractory or Recurrent Neuroblastoma in Children
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
Neuroblastoma is an embryonal tumor originated from primitive neural crest cells. It is the most common extracranial solid tumor in children.
- Trial name
- NCT04842526
- Testing
- Anlotinib and irinotecan combined with temozolomide
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Thyroid Cancer
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
- Trial name
- NCT04309136
- Testing
- Anlotinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Fudan University
Diffuse Large B-cell Lymphoma
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
This is an open-label, single-center, single-arm study to evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules in subjects with diffuse large B-cell lymphoma.
- Trial name
- NCT04827004
- Testing
- Anlotinib Hydrochloride Capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recurrent High-grade Glioma
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of anlotinib in treatment of recurrent high-grade glioma.
- Trial name
- NCT04822805
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people
- Sponsor
- First People's Hospital of Hangzhou
Chronic Graft-versus-host-disease
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic…
- Trial name
- NCT04232397
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Esophageal Squamous Cell Carcinoma
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of anlotinib combined with sindilimab as second-line treatment for advanced esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT04813406
- Testing
- Anlotinib + Sintilimab
- Volunteers
- 53 people
- Sponsor
- Henan Provincial People's Hospital
Advanced Biliary Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced…
- Trial name
- NCT04809142
- Testing
- TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection
- Where
- 17 sites in China
- Volunteers
- 392 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in patients with sensitive EGFR mutations advanced non-small cell lung cancer.
- Trial name
- ALTER-L004 (NCT03736837)
- Testing
- Anlotinib Plus Icotinib
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
SHR-1210, Anlotinib
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better…
- Conditions
- SHR-1210, Anlotinib, Advanced Esophageal Squamous Cell Cancer
- Trial name
- NCT04797507
- Testing
- SHR-1210 plus Anlotinib
- Volunteers
- 33 people
- Sponsor
- Peking Union Medical College Hospital
Non Small Cell Lung Cancer
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in patients with sensitive EGFR concomitant mutations advanced non-small cell lung cancer
- Trial name
- SAINT (NCT04797806)
- Testing
- Anlotinib, Icotinib
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Thermal Ablation
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
In this study, investigators aimed to evaluated the efficacy and safety of microwave ablation combined with anlotinib and TQB2450 Solution in patients with advanced hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Thermal Ablation, Anlotinib, PDL-1
- Trial name
- NCT04665609
- Testing
- Anlotinib and TQB2450 solution, TQB2450 solution
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Gastric Cancer, Colo-rectal Cancer
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.
- Trial name
- NCT04777162
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Non Small Cell Lung Cancer
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
- Trial name
- NCT04762030
- Testing
- Durvalumab Anlotinib Carboplatin Nab-paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
HER2-negative Breast Cancer, Gastric Adenocarcinoma
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Homologous Recombination Repair (HRR) gene mutations can be detected in many solid tumors, patients with HRR gene mutations may benefit from PARP inhibitor.
- Conditions
- HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer
- Trial name
- NCT04764084
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Stage III Adult Soft Tissue Sarcoma
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for neoadjuvant treatment of locally advanced soft tissue sarcoma.
- Trial name
- NCT04765228
- Testing
- Pegylated liposomal doxorubicin, Anlotinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Yong Chen
Relapsed Small Cell Lung Cancer, Anlotinib
A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer.
- Trial name
- NCT04757779
- Testing
- anlotinib hydrochloride combined with irinotecan or docetaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First People's Hospital of Hangzhou
SCLC, Extensive Stage, Lung Cancer
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.
- Conditions
- SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04731909
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Military Medical University
MGMT-Unmethylated Glioblastoma
Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.
- Trial name
- NCT04725214
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine